CD133/CD166/Ki-67 Triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 2, 2014, Pages 161-170

  Mǎrgaritescu, Claudiu ^a   Pirici, Daniel ^a   Cherciu, Irina ^a   Bǎrbǎlan, Alexandru ^a   Cârtânǎ, Tatiana ^a   Sǎftoiu, Adrian ^a,b  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CD133; CD166; Colocalization coefficient; Colon cancer; Colon cancer stem cells; Ki 67

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD133 ANTIGEN; CELL MARKER; KI 67 ANTIGEN; ALCAM PROTEIN, HUMAN; FETOPROTEIN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; NERVE CELL ADHESION MOLECULE; PEPTIDE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DYSPLASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER METASTASIS; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR GROWTH; COLONIC NEOPLASMS; DISEASE COURSE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES, NEURONAL; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; FETAL PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOPROTEINS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PEPTIDES; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84901934512     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 2008;67:253-256.
3. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009;18:1688-1694.
4. Bilchik AJ, DiNome M, Saha S, et al. Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg 2006;141:527-533.
5. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006;93:1115-1122.
6. Fabrizi E, di Martino S, Pelacchi F, Ricci-Vitiani L. Therapeutic implications of colon cancer stem cells. World J Gastroenterol 2010;16:3871-3877.
7. Ong CW, Kim LG, Kong HH, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010;23:450-457.
8. Saigusa S, Tanaka K, Toiyama Y, et al. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep 2010;24:345-350.
9. Zhang SS, Han ZP, Jing YY, et al. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012;10:85.
10. Abdul Khalek FJ, Gallicano GI, Mishra L. Colon cancer stem cells. Gastrointest Cancer Res 2010;Suppl 1:S16-S23.
11. Papailiou J, Bramis KJ, Gazouli M, Theodoropoulos G. Stem cells in colon cancer. A new era in cancer theory begins. Int J Colorectal Dis 2011;26:1-11.
12. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. Stem Cells 2012;30:363-371.
13. Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010;1:387-395.
14. Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382-390.
15. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021.
16. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Trafic 2001;2:82-91.
17. Giebel B, Corbeil D, Beckmann J, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 2004;104:2332-2338.
18. Coco C, Zannoni GF, Caredda E, et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res 2012;31:71.
19. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-1289.
20. Kawamoto A, Tanaka K, Saigusa S, et al. Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy. Exp Ther Med 2012;3:403-409.
21. Takahashi S, Kamiyama T, Tomaru U, et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010;24:1201-1212.
22. Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258-2264.
23. Bowen MA, Patel DD, Li X, et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995;181:2213-2220.
24. Swart GW. Activated leukocyte cell adhesion molecule (CD166/ ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 2002;81:313-321.
25. van Kempen LC, Nelissen JM, Degen WG, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem 2001;276:25783-25790.
26. Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 2008;151:122-128.
27. Ihnen M, Muller V, Wirtz RM, et al. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 2008;112:419-427.
28. Mezzanzanica D, Fabbi M, Bagnoli M, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008;14:1726-1733.
29. Minner S, Kraetzig F, Tachezy M, et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol 2011;42:1946-1952.
30. Shiraishi Y, Moriki T, Hara H, Araki K, Kozuru M, Sandberg AA. Malignant lymphoma antigen expressed in nude mouse tumor cells derived from carcinogen-transformed Bloom's syndrome B-lymphoblastoid cell lines. Cancer Res 1990;50:3106-3112.
31. Thompson HS, Corbett JJ. Asymmetry of pupillomotor input. Eye (Lond) 1991;5:36-39.
32. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27:844-850.
33. Tachezy M, Zander H, Gebauer F, et al. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients. J Surg Res 2012;177:e15-e20.
34. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/ CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004;57:1160-1164.
35. Hamilton SR, Vogelstein B, Kudo S, et al. Tumours of the colon and rectum. In:Hamilton SR, Aaltonen L A, eds. Pathology and Genetics of Tumours of the Digestive System. World Health Organisation classification of tumors. Lyon: IARC Press, 2000:104-119.
36. AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010:143.
37. Pirici D, Mogoanta L, Kumar-Singh S, et al. Antibody elution method for multiple immunohistochemistry on primary antibodies raised in the same species and of the same subtype. J Histochem Cytochem 2009;57:567-575.
38. Zinchuk V, Zinchuk O, Okada T. Quantitative colocalization analysis of multicolor confocal immunofluorescence microscopy images: pushing pixels to explore biological phenomena. Acta Histochem Cytochem 2007;40:101-111.
39. Levin TG, Powell AE, Davies PS, et al. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology 2010;139:2072-2082.
40. Arena V, Caredda E, Cufino V, et al. Differential CD133 expression pattern during mouse colon tumorigenesis. Anticancer Res 2011;31:4273-4275.
41. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008;99:1578-1583.
42. Hostettler L, Zlobec I, Terracciano L, Lugli A. ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J Gastroenterol 2010;16:732-739.
43. Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009;16:3488-3498.
44. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008;8:48.
45. Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol 2008;214:3-9.
46. Hermansen SK, Christensen KG, Jensen SS, Kristensen BW. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 2011;59:391-407.
47. Sgambato A, Errico F, Caredda E, Puglisi MA, Cittadini A. Divergent expression of CD133 in different studies: the need for a consensus panel? Int J Cancer 2011;128:2247-2249.
48. Chen S, Song X, Chen Z, et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One 2013;8:e56380.
49. Haraguchi N, Ohkuma M, Sakashita H, et al. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008;15:2927-2933.
50. Chu P, Clanton DJ, Snipas TS, et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009;124:1312-1321.
51. Muraro MG, Mele V, Daster S, et al. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med 2012;1:592-603.
52. Feng HL, Liu YQ, Yang LJ, et al. Expression of CD133 correlates with differentiation of human colon cancer cells. Cancer Biol Ther 2010;9:216-223.
53. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology 2009;55:284-293.
54. Hongo K, Kazama S, Sunami E, et al. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. Med Oncol 2012;29:2849-2857.
55. Xi HQ, Zhao P. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 2011;64:498-503.
56. Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008;15:638-648.
57. Li G, Liu C, Yuan J, et al. CD133(+) single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential. Clin Exp Metastasis 2010;27:517-527.
58. Langan RC, Mullinax JE, Ray S, et al. A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. J Cancer 2012;3:231-240.